IBDEI387 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,54219,1,4,0)
 ;;=4^I71.4
 ;;^UTILITY(U,$J,358.3,54219,2)
 ;;=^5007789
 ;;^UTILITY(U,$J,358.3,54220,0)
 ;;=I73.9^^256^2762^19
 ;;^UTILITY(U,$J,358.3,54220,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54220,1,3,0)
 ;;=3^Peripheral Vascular Disease,Unspec
 ;;^UTILITY(U,$J,358.3,54220,1,4,0)
 ;;=4^I73.9
 ;;^UTILITY(U,$J,358.3,54220,2)
 ;;=^184182
 ;;^UTILITY(U,$J,358.3,54221,0)
 ;;=I82.891^^256^2762^14
 ;;^UTILITY(U,$J,358.3,54221,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54221,1,3,0)
 ;;=3^Embolism/Thrombosis Oth Spec Veins,Chronic
 ;;^UTILITY(U,$J,358.3,54221,1,4,0)
 ;;=4^I82.891
 ;;^UTILITY(U,$J,358.3,54221,2)
 ;;=^5007939
 ;;^UTILITY(U,$J,358.3,54222,0)
 ;;=I82.890^^256^2762^13
 ;;^UTILITY(U,$J,358.3,54222,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54222,1,3,0)
 ;;=3^Embolism/Thrombosis Oth Spec Veins,Acute
 ;;^UTILITY(U,$J,358.3,54222,1,4,0)
 ;;=4^I82.890
 ;;^UTILITY(U,$J,358.3,54222,2)
 ;;=^5007938
 ;;^UTILITY(U,$J,358.3,54223,0)
 ;;=E78.0^^256^2763^12
 ;;^UTILITY(U,$J,358.3,54223,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54223,1,3,0)
 ;;=3^Pure Hypercholesterolemia
 ;;^UTILITY(U,$J,358.3,54223,1,4,0)
 ;;=4^E78.0
 ;;^UTILITY(U,$J,358.3,54223,2)
 ;;=^5002966
 ;;^UTILITY(U,$J,358.3,54224,0)
 ;;=E78.1^^256^2763^13
 ;;^UTILITY(U,$J,358.3,54224,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54224,1,3,0)
 ;;=3^Pure Hyperglyceridemia
 ;;^UTILITY(U,$J,358.3,54224,1,4,0)
 ;;=4^E78.1
 ;;^UTILITY(U,$J,358.3,54224,2)
 ;;=^101303
 ;;^UTILITY(U,$J,358.3,54225,0)
 ;;=E78.2^^256^2763^11
 ;;^UTILITY(U,$J,358.3,54225,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54225,1,3,0)
 ;;=3^Mixed Hyperlipidemia
 ;;^UTILITY(U,$J,358.3,54225,1,4,0)
 ;;=4^E78.2
 ;;^UTILITY(U,$J,358.3,54225,2)
 ;;=^78424
 ;;^UTILITY(U,$J,358.3,54226,0)
 ;;=I10.^^256^2763^3
 ;;^UTILITY(U,$J,358.3,54226,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54226,1,3,0)
 ;;=3^Essential Primary Hypertension
 ;;^UTILITY(U,$J,358.3,54226,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,54226,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,54227,0)
 ;;=I11.9^^256^2763^10
 ;;^UTILITY(U,$J,358.3,54227,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54227,1,3,0)
 ;;=3^Hypertensive Heart Disease w/o Heart Failure
 ;;^UTILITY(U,$J,358.3,54227,1,4,0)
 ;;=4^I11.9
 ;;^UTILITY(U,$J,358.3,54227,2)
 ;;=^5007064
 ;;^UTILITY(U,$J,358.3,54228,0)
 ;;=I11.0^^256^2763^9
 ;;^UTILITY(U,$J,358.3,54228,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54228,1,3,0)
 ;;=3^Hypertensive Heart Disease w/ Heart Failure
 ;;^UTILITY(U,$J,358.3,54228,1,4,0)
 ;;=4^I11.0
 ;;^UTILITY(U,$J,358.3,54228,2)
 ;;=^5007063
 ;;^UTILITY(U,$J,358.3,54229,0)
 ;;=I12.0^^256^2763^8
 ;;^UTILITY(U,$J,358.3,54229,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54229,1,3,0)
 ;;=3^Hypertensive Chr Kidney Disease w/ ESRD
 ;;^UTILITY(U,$J,358.3,54229,1,4,0)
 ;;=4^I12.0
 ;;^UTILITY(U,$J,358.3,54229,2)
 ;;=^5007065
 ;;^UTILITY(U,$J,358.3,54230,0)
 ;;=I13.10^^256^2763^6
 ;;^UTILITY(U,$J,358.3,54230,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54230,1,3,0)
 ;;=3^HTN Hrt & Chr Kdny Dis w/o Hrt Fail w/ Stg 1-4 Chr Kdny
 ;;^UTILITY(U,$J,358.3,54230,1,4,0)
 ;;=4^I13.10
 ;;^UTILITY(U,$J,358.3,54230,2)
 ;;=^5007068
 ;;^UTILITY(U,$J,358.3,54231,0)
 ;;=I13.0^^256^2763^4
 ;;^UTILITY(U,$J,358.3,54231,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54231,1,3,0)
 ;;=3^HTN Hrt & Chr Kdny Dis w/ Hrt Fail w/ Stg 1-4 Chr Kdny
 ;;^UTILITY(U,$J,358.3,54231,1,4,0)
 ;;=4^I13.0
 ;;^UTILITY(U,$J,358.3,54231,2)
 ;;=^5007067
 ;;^UTILITY(U,$J,358.3,54232,0)
 ;;=I13.11^^256^2763^7
 ;;^UTILITY(U,$J,358.3,54232,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,54232,1,3,0)
 ;;=3^HTN Hrt & Chr Kdny Dis w/o Hrt Fail w/ Stg 5 Chr Kdny
